After bottoming out at the end of May, BioWorld’s Drug Developers Index is making a slow, tedious climb back upwards. The index was down 23.18% for the year as of July 27, which is better than where it was at the end of each of the three prior months. It is following the same curve as the Nasdaq Biotechnology Index and the Dow Jones Industrial Average, which are down by 16.47% and 11.39%, respectively.
The U.S. FDA has approved fewer drugs and biologics in the first half of 2022 than in each of the five prior years and only one new molecular entity has received clearance since the end of May. While the volume of regulatory news is slightly down from last year, FDA approvals are showing a much deeper decline of 19.8%.
As neurological disease stocks begin to move in the right direction, and a potential U.S. FDA approval nears for a major depressive disease drug, shares are still down by 11.68% this year. BioWorld’s Neurological Diseases Index is following a similar path as the Nasdaq Biotechnology Index (NBI), which hit bottom at the end of May and has begun to climb since then. Still, NBI is down 15.92% this year, while the Dow Jones Industrial Average is down 12.41%.
The value of med-tech mergers and acquisitions in the first half of 2022 are at a five-year high and about 84% ahead of last year. The volume of M&As fell significantly in the second quarter, however, with only 104 completed that were worth $46.5 billion, 27.8% less than the first quarter’s value of $64.7 billion. Regardless, M&As in the first half of 2022 are towering over each of the four prior years’ first two quarters, with a total completed of 276 worth $110.9 billion.
RSS
